Topline data were announced from a phase 3b trial evaluating investigational semaglutide 7.2mg in adults with obesity.

Wegovy uses the same active ingredient (semaglutide) and can be prescribed for weight loss for people with obesity ... we created an Ozempic dosage chart based on expert insights and the dosing ...

Heymsfield said more data are needed on whether the safety profile of semaglutide 7.2 mg differs from the 2.4 mg dose. Steven B. Heymsfield “The question is if that extra weight loss is worth th ...

At the least, the new 7.2mg results point to scope for hiking the semaglutide dose in CagriSema to chase down that weight-loss target. The company is also running a phase 3b trial of 7.2mg ...

Further, 33.2% of patients on the highest semaglutide dose achieved weight loss of at least 25% after the 72-week mark, versus 16.7% of patients on semaglutide 2.4 mg and 0% of patients on placebo ...

The result is the growth of a niche industry of so-called compounding pharmacies selling “homemade” versions of these weight loss ... much semaglutide-like substance is in each dose can ...

Novo Nordisk's high dose Wegovy (semaglutide) has shown improved weight loss while remaining safe and tolerable. In the Phase IIIb STEP UP trial, 7.2mg Wegovy demonstrated statistically ...

Findings showed semaglutide 7.2mg demonstrated a statistically significant and superior weight loss compared with placebo at week 72. Topline data were announced from a phase 3b trial evaluating ...